Introduction
Inherited primary immunodeficiencies (PID), most notably severe combined immunodeficiencies (SCIDs), have become central to the field of clinical gene therapy. Here, we highlight recent progress and discuss which recent developments are most likely to lead to clinical benefits over the next few years.
As well as being well characterized at the molecular level, there are three key reasons why these disorders have been at the forefront of the field.
(i) Rare somatic reversion events in a small number of affected children have revealed that correctly functioning stem or progenitor cells can, in some circumstances, have an important survival advantage, and, thereby, mediate extensive immunological repopulation. 1 These events are spontaneous new mutations, which lead to restoration of the wild-type sequence (or novel mutations, which can compensate for the original mutation). As a result cells carrying the original mutation are replaced by revertants that have regained the native
In brief Progress
The molecular basis of insertional mutagenesis following gene therapy for severe combined immunodeficiency (SCID)-X1 has been characterized in detail. Adenosine deaminase deficiency (ADA) SCID gene therapy has mediated sustained clinical benefit with no evidence of vector related toxicity. The mechanism of clonal expansions and transgene silencing following retroviral gene therapy for Chronic Granulomatous Disease has been elucidated. Gene therapy for Wiskott-Aldrich Syndrome (WAS) has been initiated.
Prospects
Other immune and haematological disorders are good candidate disorders. For some patients without human leukocyte antigen (HLA)-matched donors, gene therapy may become a standard of care. Optimized combinations of conditioning and effective gene transfer will enhance efficiency and safety of gene therapy protocols. Self-inactivating gamma-retroviral and lentiviral vectors are entering clinical testing, and will be used more widely. New technologies, including targeted integration and gene editing, hold promise for treatment of inherited immunodeficiencies in the longer term.
phenotype and, thus, acquired a selective growth advantage.
(ii) Allogeneic haematopoietic stem cell transplantation (HSCT) is now routine therapy when a human leukocyte antigen (HLA)-matched donor is available and rates of cure have significantly improved with increasing experience. 2 Lessons from transplantation have strongly influenced gene therapy for immunodeficiency. Under some circumstances, donor cells have been found to have such a strong survival advantage that stable engraftment can be achieved with minimal or no pre-conditioning. In other cases, low levels of donor chimaerism (the ratio of donor:recipient cells in the circulation), or engraftment restricted to the T-cell lineage, has been sufficient to achieve symptom control. (iii) Haematopoietic stem cell transplantation can be readily harvested and manipulated ex vivo; thus, issues relating to in vivo administration of vectors can be circumvented.
These disease-specific features have fashioned progress in gene therapy for two decades, and will continue to influence under what circumstances patients are enrolled into future clinical studies. In the context of a fully HLA-matched family donor, transplantation will remain the treatment of choice, but for a large number of patients without suitable donors, gene therapy is likely to be an important alternative option.
The molecular basis of insertional mutagenesis following gene therapy for SCID-X1 has been characterized in detail
Severe combined immunodeficiency (SCID)-X1 is caused by defective expression of the interleukin-2 (IL-2) receptor common g-chain (IL2RG, gc) gene leading to defective expression of receptor chains for IL2, IL4, IL7, IL9, IL15 and IL21. Phase-I gene therapy studies have been completed using MFG-gc retroviral vectors for SCID-X1. Careful monitoring and advances in molecular techniques have led to detailed mapping of retroviral insertion sites in both the Paris and London studies. 3, 4 As well as insertional transactivation of the LIM domain only 2 (LMO2) proto-oncogene, additional sites close to BMI1 (involved in transcriptional control) and CCND2 (a cell-cycle protein) have been implicated in leukaemogenesis. 4 Further abnormalities in blast cell populations have been detected in some patients, including activating mutations of NOTCH-1 (important for T-cell survival and proliferation), chromosomal translocations and deletion of tumour-suppressor genes. 3 In the Paris study, four of nine successfully treated patients have now developed leukaemia between 31-68 months after the procedure (Table 1) . In three patients, chemotherapy has been sufficient to eliminate leukaemic blasts and was followed by regeneration of a polyclonal T-cell repertoire. One patient has died from refractory leukaemia. In London, one of 10 patients treated also developed leukaemia within 2 years of treatment, and this was similarly associated with LMO2 transactivation. However, this patient also had additional chromosomal changes, including a gain-of-function NOTCH1 mutation, a chromosomal translocation involving the T-cell receptor-b region and deletion of the tumour suppressor gene locus cyclin-dependent kinases-2A (CDKN2A). A good response to standard UK chemotherapy protocols for acute lymphoblastic leukaemia led to recovery of a normal T-cell repertoire. Extensive retroviral insertion site mapping has now been undertaken across both patient cohorts and the findings have fashioned our understanding of retroviral integration and insertional transactivation.
Most retroviral insertions occurred within or very close to genes, especially genes that were highly expressed in the CD34 + stem cells during time of transduction, with around 25% of integrants being Gene therapy for inherited immunodeficiencies W Qasim et al detected at common integration sites. 5 Genes encoding proteins with kinase or transferase activity, or involved in phosphorus metabolism, were over-represented in post-thymic CD3 + T cells as compared with CD34 + progenitor cell populations. 6 These findings support the notion that the genomic site of retroviral integration influences the survival potential of transduced cells, as well as their ability to engraft, differentiate and expand.
There remains considerable controversy whether insertional events alone account for mutagenesis in these patients, or whether signalling via the gc-transgene mediates transformation. Animal studies have produced conflicting data regarding the contribution of gc towards uncontrolled T-cell proliferation, although the majority of data supports a permissive role. There have subsequently been extensive preclinical efforts to incorporate less mutagenic regulatory elements and limit the risk of mutagenesis by adopting self-inactivating configurations (SIN vectors), or adding insulator elements and suicide genes. 7 Immune reconstitution after SCID-X1 gene therapy
In both studies sustained T-cell reconstitution has been observed, but there was low-level myeloid and B-cell marking, which may help explain why continued immunoglobulin replacement therapy may be required for some patients. Comparisons with immune reconstitution following unconditioned HSCT are revealing. Patients often have good donor T-cell recovery, with similar kinetics of reconstitution, but retain dysfunctional recipient B-cell immunity. Interestingly, natural killer cell reconstitution is also often poor following unconditioned transplantation, suggesting that although T cells and stem cell populations with T-cell differentiation potential readily engraft, chemotherapy is required to ensure efficient engraftment of less committed stem cell populations.
Poor immune reconstitution in older patients
The results of SCID trials conducted by the NIH were also recently reported. In these studies, three older (aged 10-14 years) patients who had previously undergone allogeneic HSCT, but had poor immunological recovery, were treated by retroviral gene therapy targeting mobilized CD34 + stem cells from peripheral blood. 8 The MFG vector used was pseudotyped with the Gibbon Ape Leukaemia virus and was similar to that used in the London study. All patients had evidence of gene marking, but only one had improvement (albeit limited) of T-cell function, and there was no evidence of clonal expansion or insertional mutagenesis. 8 Rescue treatment of such patients, particularly for older children, is extremely challenging and is probably related to agerelated thymic involution resulting in limited thymopoiesis despite satisfactory stem cell transduction.
Late-onset systemic complications following HSCT for SCID-X1 include development of serious wart lesions caused by human papilloma virus infection. Two patients have developed such lesions following gene therapy, suggesting that despite good T-cell reconstitution, patients may continue to harbour specific immunological defects (and possibly defects in nonhaematopoietic tissues such as keratinocytes). Despite these limitations, and the concerns regarding insertional mutagenesis, it should be emphasized that all surviving patients are clinically well and are leading relatively unrestricted lifestyles at home and at school.
In deciding which patients may be suitable candidates for gene therapy in future studies, progress in conventional allogeneic HSCT for SCID-X1 has to be considered. The most recent survival analysis from European monitoring studies indicate exceptional survival (approaching 90% at 5 years) following both fully matched family and unrelated donor grafts. Thus, if a suitable HLA-matched donor is available, allogeneic transplantation would be the therapy of first choice. In the absence of a matched donor, haploidentical (usually parental) donors are usually available. Improvements in outcomes following such grafts, which usually comprise CD34 + -selected stem cells or stringent T-cell depletion, have been notable in recent years, with around 70% of infants surviving. Outcome seems particularly good for younger patients, although morbidity still arises from the use of conditioning chemotherapy. With such advances, the number of infants eligible for phase-I/II gene therapy protocols for SCID-X1 will inevitably be reduced, and such studies may be best undertaken using harmonized multicentre protocols as will be the case for an upcoming study using a SIN gamma-retroviral vector configuration. Regulatory approval has recently been granted to commence trials in UK for infants with SCID-X1 for whom a suitable HLA-matched stem cell donor is not available.
ADA SCID gene therapy mediates sustained clinical benefit with no evidence of vector-related toxicity Although adenosine deaminase deficiency (ADA) -SCID and SCID-X1 have a similar clinical presentation and are managed in a similar manner, there are important differences in their molecular basis that influences patterns of immune reconstitution. Deficiency of ADA leads to accumulation of the substrates deoxyadenosine and deoxyadenosinetriphosphate, which are toxic to lymphocyte development and function. ADA is a ubiquitously expressed enzyme and its expression in trans is sufficient to mediate systemic detoxification and promote lymphocyte development. Thus, enzyme replacement therapy with PEG-ADA is usually initiated at diagnosis and can support partial T cell reconstitution.
Recent animal transplantation studies have shown that endogenous ADA-deficient lymphocytes can be rescued by enzyme derived from ADA + allogeneic donor cells. 9 In humans, infants receiving unconditioned stem cell grafts can develop mixed T-cell chimaerism, where because donor cells mediate systemic detoxification the host can support the development of endogenous ADAdeficient T-cell populations. These observations support the decision to withdraw ADA enzyme replacement therapy ahead of gene therapy (or indeed allogeneic transplantation) as an important measure to ensure a selective advantage for only the gene-corrected infused cells. Similarly, there is now good evidence from recent clinical trials that preconditioning, whereby chemotherapy is used to ablate the host haematopoietic system, is necessary to facilitate engraftment of transduced stem cells.
Comparison of reconstitution kinetics between
Gene therapy for inherited immunodeficiencies W Qasim et al protocols using conditioning or no conditioning suggests that prior ablation of the bone marrow enhances immune recovery. Reduced, partially myeloablative, doses of chemotherapy with melphalan or low-dose busulphan appear to be sufficient to secure long-term successful engraftment of gene-modified stem cells. However, there is also some evidence that infants with ADA may be more prone to chemotherapy-related toxicity than other infants. Engel et al. reported non-vector-related complications in one patient with ADA-SCID who discontinued ADA enzyme replacement, before receiving an infusion of autologous gene-modified CD34 + cells after low-dose busulphan cytoreduction. Sustained pancytopenia and negligible gene marking led clinicians to re-infuse previously stored autologous bone marrow. The patient had hypocellular marrow and evidence of trisomy-8, which was traced to pre-existing trisomy-8 mosaicism.
10 Patients with such trisomy-8 mosaicism are prone to persistent cytopaenia and their altered bone marrow microenvironment may well interfere with stem engraftment.
Studies in Italy, the United States of America, Japan and the United Kingdom have now treated over 30 infants with ADA deficiency using retroviral vectors, and sustained gene marking was observed in most patients with B67% showing successful immune recovery. 11 Aiuti et al. have recently reported further data from 10 patients treated in Milan using a busulphan-based conditioning protocol (4 mg kg À1 ). The average CD34 + cell dose was 8.2 Â 10 6 cells kg
À1
, with a mean gene transduction efficiency of 28.6%. These levels of transduction are similar to those of other studies, but the large number of CD34 + cells infused may be important for the success seen in this study. High levels of gene marking were seen in peripheral T (88% marking), B (52%) and natural killer (59%) cells. Nine patients showed effective T-cell reconstitution, with five patients also showing functional humoral immune recovery. In London five patients were treated using a melphalan-based conditioning protocol. The retroviral vector was different from that used in Milan and used the viral Spleen Focus Forming virus (SFFV)-LTR promoter for ADA gene transcription. Two patients show functional immune recovery and are clinically well. In two other individuals, immune recovery was limited by a poor initial stem cell harvest or suboptimal transduction efficiency (o5%). In a fifth individual, poor T-cell recovery, despite an adequate stem cell dose and transduction and gene marking in peripheral cells, was attributed to irreversibly compromised thymic function at the time of gene therapy. Although this patient was no older than others treated, low levels of residual thymic function probably compromised the level of T-cell reconstitution. Encouraging results have also been recently reported in a similar study at NIH and in Japan two patients have been treated using retroviral vectors after PEG-ADA withdrawal, but without chemotherapy before reinfusion of transduced cells. 11 The kinetics of T-cell recovery were slower and final T-cell numbers were lower than those observed in trials using chemotherapy conditioning, and it will be important to determine whether there is emergence of naïve T cells. Overall, these data argue that cytoreductive therapy may be important for the initial engraftment of a greater number of gene transduced cells.
Integration-site data from ADA studies
As in the SCID-X1 study, integration-site data have shown that preferred retroviral insertion sites included gene-rich regions, transcriptionally active genes and promoter regions. Cells from five patients were studied in detail, including transduced CD34 + stem cell populations before infusion, and bone marrow or peripheral blood haematopoietic cells isolated from patients up to 4 years after treatment. 12 Although integration hotspots were identified and sites close to LMO2, BCL2, BLM and CCND2 genes were detected, there was no evidence of clonal dominance and there have been no reported cases of insertional leukaemogenesis. A high number of distinct insertion sites were detected in T cells, with 10-to 100-fold less sites in myeloid lineage cells, indicating preferential lymphoid engraftment, although multipotent HSC engraftment was confirmed because 13% of integration sites were shared by T cells and granulocytes.
Studies have remained open and continue to recruit children for whom HLA-matched stem cell donors are not available. The alternative option of HLA-mismatched transplantation is not as attractive as for SCID-X1, as survival has not improved to the same extent and remains B50% at 5 years. This maybe a reflection of the systemic nature of ADA deficiency, the greater risk of underlying dysfunction in other organ systems such as the lungs and gut and the reduced tolerance of these patients to chemotherapy. Although continuation of PEG-ADA replacement therapy shows significant benefit, the cost can be prohibitive and there are question marks over longer term efficacy. The overall efficacy and safety associated with ADA gene therapy is impressive and with time gene therapy may prove to be an important alternative option for patients lacking HLAmatched stem cell donors. Why adverse insertional events have been encountered following gene therapy for SCID-X1, but not ADA deficiency, is not known, although disease-specific factors may be important.
Clonal expansions and transgene silencing following retroviral gene therapy for chronic granulomatous disease
Chronic granulomatous disease (CGD) is a rare neutrophil disorder, the X-linked form arising due to mutations in the flavocytochrome b gene (CYBB) encoding the gp91 phox (Nox2) subunit of the phagocyte nicotinamide dinucleotide phosphate (NADPH) oxidase. HSCT can cure CGD, but is generally only considered if a fully HLA-matched donor is available. In Germany, retroviral vectors expressing gp91 phox were used to modify CD34 + stem cells before reinfusion following low-dose busulphan chemotherapy pre-conditioning. In two adult patients, gene marking in peripheral blood leukocytes of up to 30% was detectable and sustained superoxide production in neutrophils was demonstrated and was associated with clearance of long-standing infections. Subsequent expansion of gene-modified cells was noted and was attributed to transactivating retroviral integrations close to transcription factor genes MDS1/EVI1, PRDM16 or the gene SETBP1. Of three patients treated, one died 27 months after treatment due to severe sepsis
Gene therapy for inherited immunodeficiencies W Qasim et al and multi-organ failure. Gene-marked cells were still detectable, but CpG methylation within the viral LTR had resulted in greatly reduced transgene expression. Similar effects were also observed for a second patient who has subsequently undergone successful HSCT. 13 Interestingly, the CpG methylation was restricted to promoter regions of the viral LTRs, causing reduced expression of gp91 phox , but enhancer elements were not methylated and, thus, transactivation of nearby genes persisted. This explains why integration analysis detected clonal expansions of gene-modified cells, while NADPH oxidase activity, dependent on transgene expression, was absent. Subsequently, chromosomal instability and haematological abnormalities, including monosomy-7, were observed. Three additional patients have been treated at our own centre using the same vector and a melphalan-based, non-myeloablative preconditioning regimen. Although persistence of genemodified cells was limited, there were transient clinical benefits, including clearance of established fungal disease, in one patient. Similarly, Kim et al. reported treating two patients without evidence of clonal expansions 14 and Malech et al. have reported clearance of longstanding staphylococcal infection in a patient receiving retrovirally transduced stem cells after conditioning. 15 Again, although persistence of gene-modified cells was limited, as a transient rescue therapy this approach has offered valuable benefit. Why gene-modified cells failed to persist in the absence of vector-driven clonal expansions is not clear, but patients with CGD may have a suboptimal bone marrow environment, which hampers mobilization required for the purposes of autologous stem cell harvest and fails to support engraftment of transduced stem cells.
Gene therapy for Wiskott-Aldrich Syndrome gets underway
Wiskott-Aldrich Syndrome (WAS) is an X-linked disorder characterized by immune deficiency, thrombocytopenia and eczema, and with age, patients become prone to haematological malignancies and autoimmunity. The WAS gene encodes a cytoskeletal regulation protein in haematopoïetic lineage cells, which is important for platelet production and immune cell activation and motility. Current recommendations advocate HSCT if a suitable HLA-matched donor is available. Occasional somatic reversion events have suggested that functional T cells have a selective advantage in WAS, although it should be noted that there is also evidence that mixed chimaerism after transplantation may be associated with autoimmune complications, which probably arise as a result of defective immune regulation. To date, two children have received infusions of LTR-based gamma-retroviral gene-modified cells after non-myeloablative conditioning, and both had demonstrable peripheral blood leukocyte marking without evidence of clonal expansions. 16 WASP-transgenic T cells and natural killer cells show a relative increase over time (up to 70% WASP-expressing cells). No cytogenetic abnormalities have been reported in this study and although one child has had autoimmune cytopaenia, the other had marked clinical benefit. A multicentre clinical trial using a human immunodeficiency virus-1-derived lentiviral vector with endogenous gene regulatory elements is now pending (regulatory approval has recently been secured in UK), and will target CD34 + stem cells from patients without suitable HLA-matched donors.
Other candidate immune disorders may be suitable for gene therapy A number of other PID disorders are attractive candidates for gene therapy. As with the conditions already treated, transplantable primary T-cell disorders and those in which low levels of corrected cells are sufficient for therapeutic benefit are most likely to benefit. Advances include correction of murine models of SCID due to mutations in the Artemis gene. This condition is associated with increased cellular radiosensitivity and an absence of T and B cells. Grafting of lentivirally transduced HSCs into irradiated Artemis-knockout mice lead to effective T-cell reconstitution, and although in a second study 1/13 mice did develop a thymoma, this was not thought to be vector related because the recipient strain is known to be tumour prone. 17 A canine model of leukocyte adhesion deficiency, another rare neutrophil disorder characterized by serious bacterial and fungal infections, was successfully ameliorated using Foamy Virus vectors expressing the b-integrin CD18. 18 Again, preconditioning of animals using non-myeloablative conditioning was essential and relatively modest levels of gene modified cell engraftment was sufficient for the sustained resolution of symptoms. The ability of low levels of circulating neutrophils to achieve disease control in leukocyte adhesion deficiency has been confirmed in the allogeneic transplant setting where patients with relatively low levels of donor engraftment remain symptom free. As haploidentical transplantation for leukocyte adhesion deficiency is a difficult and high-risk procedure, 19 gene therapy for this condition remains highly attractive for patients without suitable HLA-matched donors. Importantly, Foamy viruses are non-pathogenic in humans and vectors may have a favourable integration profile compared with gamma-retroviral vectors.
Prospects for gene therapy for immunodeficiencies: immediate and longer term
Self-inactivating (SIN) gamma-retroviral vectors have been developed to reduce the likelihood of protooncogene transactivation. 20 These vectors have a deletion within the U3 region of the viral LTR and thus, following reverse transcription viral promoter/enhancer elements, including the CAAT and TATA boxes, are inactive. Weaker internal promoters such as the human elongation factor-1a or phosphoglycerate kinase gene promoters are used to drive transgene expression and are measurably less mutagenic in vitro and in mice (Figure 1) . 21, 22 Introduction of endogenous regulatory elements, derived from inter-species comparative analysis studies, could allow improved physiological control of gene expression. Such regulated gene expression could obviate concerns about adverse effects of continuous expressions of genes such as IL2RG. One approach Gene therapy for inherited immunodeficiencies W Qasim et al to circumvent the need to identify of all the key promoter/regulatory elements might be to incorporate the entire genomic sequence including the core promoter region and all introns as reported recently for IL2RG. 23 To reduce insertional variegation effects and the risk of proto-oncogene transactivation, insulator elements might be incorporated to act as barriers to promoter and enhancer effects. Another strategy to improve safety would be to link therapeutic genes to a suicide gene, and, thereby, allow cells to be eliminated in the event of transformational changes. This approach would be relatively crude and would result in elimination of all gene-modified cells. There is also a potential risk of immune rejection of cells encoding additional non-human genes.
A number of these preclinical advances should reach clinical testing within a period of months. The integration profile of lentiviral vectors, while still exhibiting a preference for gene-dense regions and transcriptionally active genes, may be safer than gamma-retroviral vectors, which have a preference for transcription start sites. 24 Lentiviral vectors have now been used in clinical studies, including for the rare metabolic disorder adrenoleukodystrophy. Although not a PID, the course of adrenoleukodystrophy can be ameliorated by allogeneic HSCT, and, thus, CD34 + stem cell modification by gene therapy has been attempted in a phase-I study, which used a human immunodeficiency virus-1-derived lentiviral vector. The vector encoded an internal MND (myeloproliferative sarcoma virus enhancer, negative control region-deleted, dl587rev primer-binding sitesubstituted viral promoter). Transduced autologous stem cells were re-infused after full myeloablative conditioning. Three patients have been treated with sustained gene marking in the periphery and no evidence of clonal expansions. 25 Longer follow up is required to determine whether this strategy has been efficacious. Longer term alternative approaches may hold promise. Strategies designed to correct mutations by gene editing, rather than the introduction of an additional transgene, could eliminate the need for integrating vectors and greatly improve the safety profile of stem cell gene therapy. One elegant strategy, which has recently been described, has used zinc-finger nucleases to target a common mutation in the human gc-gene. Cys 2 His 2 zinc fingers comprise zinc ion-dependent amino-acid structures, which target specific DNA base triplets. Zinc-finger assemblies have been fused to FokI endonuclease to generate artificial zinc-finger nucleases capable of inducing site-directed double stranded DNA breaks. In the presence of appropriate homologous donor DNA sequences, this can result in effective gene repair through up-regulation of homologous recombination (HR). The strategy requires multiple plasmids or viral vectors for the intracellular delivery of two defined zinc-finger nucleases (targeting opposite DNA strands), and the provision of a suitable donor template for HR. In an important recent study, Lombardo et al. used separate integration deficient lentiviral vectors to deliver the requisite elements and showed efficient gene correction of gc in cells lines and in primary cells. 26 Could this strategy deliver therapeutic benefit? Certainly SCID-X1 would be an attractive candidate disease for such an approach as even low-level gene repair should be sufficient to mediate T-cell recovery. The efficiency of the approach is being improved through the design of more efficient ZFNs and a number of similar systems designed to promote homologous recombination that are also under investigation, including engineered meganucleases. 27, 28 Each new technology will require careful evaluation and screening for off-target effects and potential toxicity.
The regulatory environment continues to evolve to meet the challenges of emerging gene-based therapies. The infrastructure requirements and the cost implications of performing stem cell manipulations under GMP conditions, as well as the longer term burden of monitoring patients over an extended period, require substantial investment. However, there is a potent health economics argument for the durable correction of childhood diseases, and once greater numbers of patients are treated using gene therapy, costs will become increasingly favourable in comparison with HSCT. 0 LTR. Insulator elements may be incorporated within the LTRs to abrogate variegation effects and reduce the risk of transactivation. Internal promoters such as elongation factor-1a or phosphoglycerate kinase are used to drive transgene expression. There is scope to link the expression of a therapeutic gene via an internal ribosomal entry sequence (IRES) element or self-cleaving peptide (F2A) to a safety gene such as the herpes simplex thymidine kinase suicide gene.
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